Invention Grant
- Patent Title: CD47 monoclonal antibodies and uses thereof
-
Application No.: US16989702Application Date: 2020-08-10
-
Publication No.: US12091467B2Publication Date: 2024-09-17
- Inventor: Zhengyi Wang , Lei Fang , Bingshi Guo , Jingwu Zang
- Applicant: I-Mab Biopharma US Limited
- Applicant Address: US MD Rockville
- Assignee: I-Mab Biopharma US Limited
- Current Assignee: I-Mab Biopharma US Limited
- Current Assignee Address: US MD Rockville
- Agency: MORRISON & FOERSTER LLP
- The original application number of the division: US15761309
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K47/68 ; A61P35/00 ; C07K16/30 ; G01N33/68
Abstract:
The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
Public/Granted literature
- US20210054093A1 Novel CD47 Monoclonal Antibodies and Uses Thereof Public/Granted day:2021-02-25
Information query
